Atorvastatin in polycystic ovary syndrome (PCOS)

Not Applicable

Completed

• Conditions: Polycystic ovary syndrome (PCOS); Nutritional, Metabolic, Endocrine; Ovarian dysfunction

• Registration Number: ISRCTN24474824
• Lead Sponsor: Hull and East Yorkshire Hospital NHS Trust (UK)

Brief Summary

1. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/21972424 2. 2019 results in: https://www.ncbi.nlm.nih.gov/pubmed/31293514 (added 15/07/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2008-05-01
• Study Start: 2008-05-09
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

1. A diagnosis of PCOS was based on Rotterdam criteria
2. Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, and androgen secreting tumours excluded by appropriate tests
3. Subjects were advised not to alter their usual dietary and exercise habits
4. Females aged 18 - 40 years

Exclusion Criteria

1. No concurrent illness
2. Patients not wishing to allow disclosure to their GPs
3. Patients not on barrier or oral progesterone contraception

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in biochemical hyperandrogenaemia, measured at baseline and after three months.

Secondary Outcome Measures

Name	Time	Method
Improvement in insulin resistance, measured at baseline and after three months.